Prospects and limits of pharmacogenetics: The thiopurine methyl transferase (TPMT) experience

American Journal of PharmacoGenomics

Volumn 3, Issue 3, 2003, Pages 149-155

  Van Aken, Jan ^a   Schmedders, Mechtild ^a   Feuerstein, Günter ^a   Kollek, Regine ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ALLELE; CLINICAL STUDY; DATA ANALYSIS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; ETHNIC GROUP; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER TOXICITY; METHYLATION; PHARMACOGENETICS; PHENOTYPE; POPULATION DISTRIBUTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THIOPURINE METHYLTRANSFERASE GENE;

ANIMALS; GENE FREQUENCY; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS;

EID: 0038345082     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303030-00001     Document Type: Review

References (39)

1. Nebert DW, Bingham E. Pharmacogenomics: out of the lab and into the community. Trends Biotechnol 2001; 19: 519-23
2. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228-31
3. Freund CL, Wilfond BS. Emerging ethical issues in pharmacogenomics: from research to clinical practice. Am J PharmacoGenomics 2002; 2 (4): 273-81
4. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-5
5. McLeod HL Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-72
6. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene TPMT in a European population. Br J Pharmacol 1998; 125: 879-87
7. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301
8. Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methytransferase. Proc Natl Acad Sci USA 1995; 92: 949-53
9. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702
10. Otterness D, Szumlanski CL, Wood TC, et al. Human thiopurine methyltransferase pharmacogenetics. J Clin Invest 1998; 101: 1036-44
11. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-6
12. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30
13. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12: 177-85
14. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73
15. Schütz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing 'two-color/shared' anchor and fluorescence-quenching hybridisation probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000; 46: 1728-37
16. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity. Gut 1996; 39: 401-6
17. Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367-70
18. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8
19. McLeod HL, Coulthard S, Thomas A, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105: 696-700
20. Brouwer C, Marinaki AM, Lambooy LHJ, et al. Pitfalls in determination of mutant alleles of the thiopurine methyltransferase gene. Leukemia 2001; 15: 1792-3
21. Rossi AM, Bianchi M, Guarnieri C, et al. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 51-4
22. Dervieux T, Medard Y, Verpillat P, et al. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy of childhood lymphoblastic leukemia with mercaptopurine. Leukemia 2001; 15: 1706-12
23. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-8
24. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9: 773-6
25. Ando M, Ando Y, Hasegawa Y, et al. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukemia. Pharmacogenetics 2001; 11: 269-73
26. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles TPMT*2 *3A *3B and *3C in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 2001; 51: 475-7
27. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase TPMT gene in Japanese. Pharmacogenetics 2001; 11: 275-8
28. Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999; 38: 944-7
29. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42
30. Hiratsuka M, Inoue T, Omori F, et al. Detection assay of rare variants of the thiopurine methyltransferase gene by PCR-RFLP using a mismatch primer in a Japanese population. Biol Pharm Bull 2000; 23: 1090-3
31. Hongeng S, Sasanakul W, Chuansumrit A, et al. Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol 2000; 35: 410-4
32. Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344: 1392-3
33. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54
34. Chocair PR, Duley JA, Simmonds HA, et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53: 1051-6
35. Stolk JN, Boerbooms AMT, de Abrcu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1858-66
36. Lennard L, Lilleyman JS, van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9
37. Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase TPMT polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38: 640-4
38. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measuremcnt for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13
39. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92